Lion Point Capital’s Edgewise Therapeutics EWTX Stock Holding History

Lion Point Capital’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$370K	Hold	9,100	–	–	1.77%	22
2026 Q1	$287K	Hold	9,100	–	–	1.71%	24
2025 Q4	$226K	Buy	+9,100	New	+$183K	1.17%	32

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Lion Point Capital's EWTX Position: Q2 2026 in Review

Lion Point Capital held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 9,100 shares worth $370K. The position accounts for 1.77% of the portfolio, ranked #22.

Lion Point Capital first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Lion Point Capital held 9,100 shares of Edgewise Therapeutics worth $370K as of Q2 2026.
Lion Point Capital left its Edgewise Therapeutics share count unchanged in Q2 2026.
Edgewise Therapeutics made up 1.77% of Lion Point Capital's portfolio in Q2 2026, its #22 holding.
Lion Point Capital first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.